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ABSTRACT
Nelson, Alexis K. The University of Memphis. May, 2021. The effects of rigidity on
energy expenditure during walking and physical activity of daily living in Parkinson Disease and
elderly adults. Advisor, Committee Chair: Dr. Douglas W. Powell.
Parkinson’s disease (PD) is a neurodegenerative disorder associated with the loss of dopamine
producing cells, resulting in motor symptoms including rigidity. There is little known on how the
mechanical symptoms of PD are related to metabolic efficiency. The purpose of this study was to
investigate the effects of rigidity on energy expenditure during walking. We hypothesized that
rigidity would positively correlate to metabolic cost of walking. 20 participants were recruited
(10 PD; 10 controls). Equipment involved included a metabolic cart to perform indirect
calorimetry (TrueOne, ParvoMedics, Sandy, UT), and an isokinetic dynamometer for passive
rigidity assessments (HUMAC, CSMi Inc, Boston, MA). PD observed significant differences in
rigidity measurements where PD had higher rigidity compared to controls. No significant
differences were observed for energy expenditure. A positive moderate correlation between total
rigidity work score and absolute VO2 was observed, where greater rigidity relates to greater
energy expenditure during walking.
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CHAPTER I

Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disorder associated with the
loss of dopamine producing cells in the basal nuclei. In time, after 80% of neuronal apoptosis,
the neurodegeneration leads to motor symptoms such as bradykinesia, postural instability,
rigidity and tremor [82]. Overall, motor symptoms negatively impact the quality of life (QoL)
and independence for PD patients [59]. A large contributor to a decreased QoL for PD stems
from the cardinal symptoms as an inability to perform daily tasks such as walking.

Gait mechanics of PD are altered and continue to digress in the ability to maintain as the
disease progresses. PD patients experience gait dysfunction through reduced gait velocity,
variability, shortened step and stride lengths, reduced range of motion, reduced width variability
and freezing of gait [23, 24, 32, 47, 63, 65, 68]. The previously mentioned adopted walking
strategies reduce the mechanical efficiency of the system to perform the task [8]. This is partially
due to the inability of the elastic musculotendon components to utilize energy conserving
strategies. To conserve energy, the musculoskeletal system stores mechanical energy in the
parallel and series elastic components during the early stages of gait. The series elastic
component represents the tendon and the intrinsic elasticity of the myofilaments. Therefore,
tendon compliance has a large influence on whole body metabolic efficiency [92] and further the
ability of the tendon to perform its part in mechanical efficiency is compromised when the
system is rigid. This mechanical inefficiency can potentially lead to an increase in metabolic
demand.
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PD patients exhibit greater metabolic costs of walking [16, 39]. In addition, higher VO2
are observed walking at preferred velocities in PD compared to healthy controls. Energy
consumption while walking is higher in PD patients compared to healthy controls [51]. Further,
energy expenditure during a 6-minute walk test has been correlated to physical activity levels for
PD patients at home [38]. This increase in energy consumption during activities of daily living
are well researched, however the connection to motor symptoms such as rigidity are not known.

In PD, an increase in energy expenditure has thought to be expressed through the
symptom of fatigue [8]. In addition, for PD a potential mechanism behind mechanical
inefficiency through the elastic components can be seen through the symptom of rigidity.
Rigidity is defined as an increased resistance to passive movements created by hypertonia and
increased intrinsic stiffness of passive connective tissues [22]. There is little research in PD on
how mechanical and metabolic efficiency is connected. An increased understanding on the
importance of the elastic components in mechanical efficiency, is necessary to identify the role
of intrinsic stiffness in PD patients on the metabolic demand for gait. Therefore, the purpose of
this study is to investigate the effects of parkinsonian rigidity on energy expenditure during
walking in individuals with PD. We hypothesize that with increasing amount of rigidity, there
will be a subsequent increase in energy expenditure during walking.
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CHAPTER II
Literature Review
Background
Parkinson’s disease (PD) is a progressive neurodegenerative disorder commonly
characterized by motor symptoms such as bradykinesia, rigidity, tremor and postural instability
[87]. Throughout the world, PD is most concentrated in the North American region [17]. Within
the United States of America, PD is the second most prevalent neurodegenerative disorder [44].
Nationally, the burden of PD exceeded $14.4 billion in 2010, leading to an estimated $22,800 in
healthcare costs per patient [44]. Not only is PD costly, but the projection of PD cases is
estimated to grow substantially over the next two decades due to the increasing elderly
population. More specifically, by 2040 from 2010 the PD population is estimated to double from
the census of 630,000 patients that year [44]. The overall prevalence in the United States is small
at 0.3% but, rates significantly increase to 1-2% in persons over the age of 65 and 4-5% for
people of 85 [87]. With an increasing population with the disease, the estimates on national and
individual debt are also bound to increase. Commonly the age of onset for PD is 60, but 10% of
those affected are 4only 21 to 45 years [87]. Therefore, all adult groups are susceptible to PD.
Individuals with PD experience numerous negative effects to their quality of life. Decreases in
health-related quality of life (HRQOL) have been shown to have increases in disease severity
[34].
Etiology
Overall, there are two types of PD; idiopathic and familial. 90% of neuropathologic PD
are idiopathic, only 10% have a familial or genetic origin [87]. For the genetic origin, six gene
mutations are currently known [87]. There are 18 chromosomal regions (termed PARK) that
3

have been found to be associated with PD onset but, research involving mutations in these areas
are unreliable. PD-related mutations are said to affect proteins similar to alpha-synuclein and
ligases like parkin as well as other molecular processes [9]. These genetic mutations are thought
to forebode the pathology underlying PD. The pathology of idiopathic PD remains unclear but
there are a few risk factors that have been identified. One factor within idiopathic PD is exposure
to pesticides. This has been found to be an environmental risk factor to aid in the onset of PD
[76].
Methods to how neuronal degeneration starts in PD are still in the research processes
relating to both familial and idiopathic origination of the disease. Researchers found in PD
oxidative stress, molecular changes and mitochondrial dysfunction contribute to neuronal
apoptosis [52]. In a similar manner the above factors simultaneously enhance genotoxic agents,
while increasing oxidative damage to proteins and lipids [54]. In idiopathic PD, an increase
amount of α-synuclein in the substantia nigra pars compacta (SNc) associates with the
aggregation of proteins. This method of aggregation has also been found in an autosomal
recessive form of familial PD formed from a mutation with the Parkin gene where the gene
protects against the toxicity of the protein α-synuclein [64]. With this mutation, a specific type of
α-synuclein is increased, making α-synuclein a common factor in both origins of PD [54]. The
accumulation of mutant α-synuclein protein is involved with the generation of Lewy bodies.
Lewy bodies simultaneously increase with pro-apoptosis factors. Functionality, Lewy bodies are
known to either act as a cytoprotective response or act as an aid to neurodegenerative processes.
Overall, Lewy bodies are an important marker to sight in the progression of PD.
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Pathology of signs and symptoms
Parkinson’s can be described as a combination of motor problems of bradykinesia,
resting tremor, rigidity, “freezing” and fatigue [22]. All of the symptoms named above stem from
the basal ganglia dysfunction. The basal ganglia are a part of the subcortical nuclei that is made
up of the caudate, putamen, globus pallidus (internal and external) and subthalamic nucleus
(SNc). Functionally, the SNc works with the basal ganglia, but anatomically the SNc is a nucleus
in the midbrain. Controls behind the basal ganglia include voluntary motor movements,
procedural learning, eye movements, cognition and emotion. PD resides in the loss of
dopaminergic neurons in the SNc. Motor symptoms such as rigidity or bradykinesia start to show
when there is a 60% reduction in dopaminergic neurons in the putamen and an 80% reduction of
dopamine [22]. The dorsal striatum, consists of the caudate and putamen, is the messenger
pathway for the basal ganglia. This system receives excitatory afferent from the cortex and
thalamus to form two pathways: indirect and direct. Both pathways are the most influential of the
basal ganglia to control movement compared to other motor pathways [88]. Most of the cells in
striatum are GABAergic (inhibits neural activity). The direct-pathway originates in the
striatonigral which receives excitatory afferents from the sensorimotor cortex and thalamus.
Direct pathways then project to GABAergic neurons in the internal globus pallidus and SNc
which then send axons to the motor nuclei of the thalamus which offsets the inhibition signal.
Direct pathways facilitate movement. Indirect-pathways originates from the striatopallidal and
acts as an inhibitory synapse on GABAergic pallidal neurons and projects to the subthalamic
nucleus. Subthalamic neurons sends axons to the internal globus pallidus and SNc which form
excitatory synapse for the inhibitory output neurons [45]. The net effect of the indirect pathway
is movement inhibition. An important role of dopamine is to regulate the two pathways through
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two receptors: D1 and D2. D1 receptors facilitate firing in the striatum, where D2 receptors
inhibit. Individuals with PD have trouble regulating the indirect and direct pathway due to the
imbalance of dopaminergic neurons. PD reduces the dopamine receptors to activate which
creates a downstream inhibition of the indirect pathway and decreased excitatory component of
the direct pathway [22, 45].
Bradykinesia
Bradykinesia is the slowness in a performed movement [7]. There are two elements to
bradykinesia; hypokinesia, which explains the smaller range of motion with slowed movements
and akinesia which refers to the late onset in order to initiate a movement [7]. Akinesia can be
divided into three parts: (1) slowness and unskillfulness of movement secondary to rigidity, (2)
absence of muscular weakness with lack of movement, and (3) difficulty to initiate movement.
The first and second type of akinesia can be helped through Levodopa medications, and through
stereotaxic thalamotomy within the ventrolateral nucleus of the thalamus [10]. The third type of
akinesia has been shown to worsen through levodopa medication but helped through
norepinephrine therapy.
In PD, one of the causes of bradykinesia is that motor units are slowed once fired and
require a higher threshold than normal to fire [19]. Movement velocity correlates to the
progression and severity of bradykinesia [10]. Bradykinesia is not inflicted by the motor control,
but rather from the basal ganglia or by disrupted movement patterns [57]. In past research,
following the disease, the initial least affected limb will grow to the same severity of the most
affected limb with time [49]. In akinetic-rigid PD, deterioration of mental status parallels
advancement in bradykinesia and independent from tremor [93]. Overall, this clarifies the reason
behind two types of PD; tremor dominant PD, and akinetic-rigid PD where majority of the
6

symptoms are expressed independently from tremor. Bradykinesia is a symptom of akinetic-rigid
PD.
Rigidity
Muscle rigidity is defined as a uniformed resistance throughout an entire passive range of
motion throughout the limb [67]. There are two elements of PD rigidity; (1) hypertonia, which is
increased resistance of the joint to passive movement and (2) uniformity of the resistance, in
which the resistance stays relatively constant across the ROM [67]. With the two elements, two
mechanisms underlay uniformed muscle rigidity. The neural-meditated excitation of shortening
muscles, i.e. the shortening reaction (SR) or the inhibition of stretched muscles i.e, stretchedinduced inhibition (SII) help increase uniformed rigidity [66, 67]. There is a neural and nonneural contribution to rigidity. As stated above, neural contributions to rigidity are ascribed as
some over-reaction of the stretch reflex mechanism. Specifically behind neural-rigidity
mechanisms, the long-latency stretch reflexes are increased in size in PD due to the use of
supraspinal pathways [73]. As a result, parkinsonian individuals should have a heightened long
latency EMG magnitude during passive stretching when compared to age matched controls. In
addition, PD experience high amounts of EMG activity during passive shortening of the muscle
[5]. Both short and long latency reflexes have been shown in sagittal plane movements. Overall,
this heightened long latency reflex and shortening reaction suggest that this reflex alteration
contributes to neural components of parkinsonian rigidity and aid in an increase resistance to
passive movements [5, 67]. The duration and magnitude of the long-latency reflex mostly
contributes to increase hypertonia in PD [8].. Increased muscular activity at rest contributes to
muscular rigidity in PD patients [8]. This is caused from brain efferent signals a need to the
muscle to contract. Past research states that this symptom is due to neural components, but
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current research is finding that non-neural components can be the cause of muscle rigidity [8, 67,
68]. Non-neural components include connective tissue, and increased stiffness in the tendons
and muscles. All of the above including: an increased muscular signal at rest, an increase in
stiffness at the tissue level, and an increased muscular effort show several mechanisms to show
the abnormalities in muscular performance in PD patients.
Biomechanics of movement
Muscular Effort / Peak Force Production and Rate of Force Development
In healthy older adults, muscular effectiveness already decreases with age;
however, not at the equivalent rates with PD [43]. An early detection for PD has been speculated
to be an increase in muscular weakness. Even in early stages of PD, power and work values
compared to healthy age matched controls were significantly decreased in the lower extremity. In
PD, previous research has shown that rate of force development, force steadiness and peak forces
are altered [72, 78]. Rate of force development is hindered and also there is a reduction in peak
maximum voluntary skeletal force output in PD patients [25, 31, 80, 81]. This has been shown
through decreases in isokinetic force production in the lower extremity of PD patients [43, 81].
Specifically, PD shows a disparity in rate of force development in early to mild-tomoderate cases [31, 72]. In addition, with an increase in performance velocity, PD patient’s
performance decreases drastically compared to healthy controls. In healthy controls the trend is
with increasing isokinetic velocity, a decline in muscle torque is expected. However, with
Parkinson’s patients this trend shows a greater disparity suggesting greater muscle weakness, and
increasing disparity with disease progression [40, 58]. Anatomically, individuals with PD have
been found to have less tendon elongation and muscle fascicle shortening, potentially having a
connection to the decrease ability to produce force quickly [79]. Overall, in PD a trend shows
8

muscle weakness. This muscle weakness also affects several performance variables that affect
activities of daily living. This reduction in muscle power has been associated with a greater fall
risk and slower walking velocities [4]. In addition, Without the ability to develop force quickly,
the risk of falling due to the inability of the patient to regain balance increases significantly [41].
Lower extremity muscles are important to perform activities of daily living such as balance,
walking, showering, and many other examples. An inability to utilize large muscle groups at a
short notice alters the quality of life of PD patients significantly. An origin for the inability to
produce force quickly could be due to rigidity. Rigidity is the increase in resistance to move a
limb through a range of motion. A way to quantify rigidity is through a work score.
Rigidity and work score have been correlated as a clinical quantitative assessment of
rigidity. Work score helps to measure the elastic, viscous and inertial components of rigidity
where velocity, length and acceleration all have a factor in resistance forces around the joint.
Another way to quantify rigidity is through the use of angular impulse at a singular moment
instead of throughout the movement [29]. Overall, PD patients show a reduction in muscle
strength, power and alteration in the musculotendon mechanics creating a potentially inefficient
system metabolically. There is an increased need to understand the relationship between how
increases in physiological demand and reductions in mechanical efficiency affect the quality of
life of PD patients. An inability to voluntarily reach a peak muscle activation could lead to
muscle weakness, where overall could lead to alternate tendon mechanics leading to a less
metabolically efficient system.
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Energy Expenditure and Gait
Metabolic Demand
Whenever muscular work is performed, energy consumption is required. In order to
move, mechanical patterns must be selected. Movement strategies are selected based on the
metabolic cost of the action [3, 15, 56]. A reduced metabolic cost can be described as the
conservation of energy exerted. Where an increased metabolic cost increases the amount of
energy exerted through an increase in task demand. Breathing strategies depict one-way energy
conservation can be quantified. A serial quick exchange of inhalation and exhalation of air can
increase the energy needed for the task [60]. The longer the task is sustained or higher intensity
the task needs, an increase in energy is required.
There is a ratio between breathing techniques and walking for energy consumption.
During walking, a higher stride rate will equate to a higher energy consumption [70]. In addition,
mechanical function can help define what physiological need is required. Human locomotion
requires the body to progressively move through continuous displacement of the center of mass
(COM). This displacement of COM in the lower extremity moves similar to an inverted
pendulum. For instance, COM vertically oscillates throughout gait cycle. During the first stage of
gait, COM projects in an upward motion for the body to fall forward. Once double support
begins, COM falls and then heel strike abruptly raises COM to initiate the gait cycle again. In
this paradigm, if movement is not impeded, the cyclical motion of the lower extremity will
sustain with little to no mechanical work required [37, 46, 86]. With this stated, work is required
during single limb stages of gait to redirect the COM [28], making the system require some
energy consumption. However, energy to continue the pendulum of walking does not need the
energy required as seen in previous research. Since the net mechanical work of the system is zero
10

without consideration of the single limb phase, additional energy conservation mechanisms must
be in work.
Musculotendon units make up the elastic components which contribute to energy
conservation during gait [28, 37].Therefore, mechanically, tendon’s help to decrease energy
expenditure in walking and muscles are composed of contractile and elastic components, making
up the energy consumption factors of walking. This relationship of musculotendon units can
fluctuate, where tendon recoil can decrease the use of muscles during gait. For example, the
Achilles tendon recoil helps decrease the use of the medial gastrocnemius during walking [48].
One way this ratio can be altered is through compliancy of the tissues. For instance, in order to
perform optimally, tendons require an appropriate stiffness [30, 48]. Tendon stiffness is affected
in PD patients, and ultimately can change the mechanisms behind musculotendon unit energy
expenditure [67].
In addition to altered tendon tissue factures, altered gait strategies of PD patients could
affect walking economy strategies as well. Compared to healthy age matched controls, PD
individuals walk with shorter stride lengths. Shorter stride lengths has been known to increase
walking economy in healthy individuals [53]. In addition, there is a greater walking economy in
PD patients compared to healthy individuals [16].

However, walking economy has not been

explained through parsing potential factors that aid in the increase of economy in PD patients
compared to healthy individuals.
Oxygen Consumption
With a higher metabolic demand, a higher consumption of oxygen is needed to continue
the task. In walking PD patients have shown to have a higher oxygen cost of walking compared
to health controls [38, 39]. Contrarily, in a study examining mild to moderate PD patients, no
11

rigidity requirement, aerobic capacity measures did not differ from predicted normal O2
consumption levels during a maximal cycle ergometer. However these patients showed that their
walking strategy was different compared to a healthy gait even when the velocities were in
normal ranges [14]. However peak VO2 was significantly lower in PD compared to healthy
controls in a separate study later on [42]. This could be due to the inclusion material for not
controlling for rigidity scores, and performing the aerobic capacity measures on an ergometer
instead of a walking task. A walking task increases the stress to the system due to the difficulty
for PD patients to perform the task.
Specifically, individuals who have PD and a shorter stride length demonstrate higher
values of oxygen cost of walking. Oxygen consumption could be a physiological predictor of
neurological walking dysfunction [39]. In PD patients, oxygen consumption averaged 64% at
their preferred comfortable pace, indicating severe impairments for economy of gait [42, 77].
This is predicted to increase the energy demands to perform daily physical activities. In addition
this all leads to a lower physiologic reserve where gait is performed at a high percentage of the
patient’s VO2 [42]. With a higher metabolic demand, shown by an increase in oxygen
consumption during a preferred walking pace, this should increase the fatigue of the PD patient
during daily activities.
Fatigue
Fatigue is frequently an early symptom of PD and approximately 58% of people with PD
reported fatigue as one of their top 3 most disabling symptoms [26]. After a nine year follow up
from the patients that reported severe fatigue symptoms showed a correlation between fatigue
and the severity of the disease [27]. In comparison to healthy patients who reported significant
fatigue: only 15% of healthy men and 29% of healthy women aged 65 to 102 years reported
12

significant fatigue [85]. PD-related fatigue has been described as an “overwhelming sense of
tiredness” or “lack of energy” [2] and may be associated with a number of social, psychological
and physiological factors including depression or anxiety [12].
Such wide-ranging descriptors of fatigue include subjective states that are independent of
activity as well as activity-related decreases in force production. Findings from broad
investigations of disease-associated fatigue are unclear and difficult to use in structuring
treatment protocols. A common factor amongst people who report fatigue have a sedentary
lifestyle. In a past study, 66% of men and 82% of women who reported fatigue, also reported a
sedentary lifestyle [85]. There are two types of fatigue: fatigue and fatigability. Activity-induced
fatigue is an important subcategory of fatigue which is more clearly identified by the term
“fatigability” [21]. Fatigability is used to set apart activity- or exercise-induced changes that
result in reduced muscle force production as opposed to the perception of fatigue which is
manifested as a general state-of-being associated with an ongoing sense of tiredness or lack of
energy. Fatigability is the result of substrate depletion at the muscle, or the inability to fire motor
units (Mus) from the central structures. Peripheral fatigue will be caused from the intra-muscular
inabilities to generate a movement in the same time as prior to the onset of fatigue, and central
fatigue will result from the motor cortex’s inability to propagate a neural signal to the muscle
[83]. Although fatigue is a prominent and disabling feature of PD, few studies have directly
investigated the origins or mechanisms underlying PD-related fatigue.
Physical Activity
Physical activity is considered to be one of the more important non-pharmaceutical strategies to improve
quality of life. Physical activity is defined as any body movement that contracts skeletal muscle
throughout the day that is unplanned, where planned physical activity is an exercise. For PD physical
activity has been shown to improve the management of symptoms, and delay disease progression [11, 61,
13

75]. However, the majority of PD patients have reported significantly less physical activity levels
compared to the general population [84]. In addition, PD population decreases physical activity more
rapidly as they age compared to the healthy population [14]. A main concern for low physical activity
rates is the effects of deconditioning. Deconditioning is associated with disuse-induced changes in muscle
and bone due to a lack of load on the system, and a secondary effect of cardiometabolic risk factors that
stent from low physical activity levels, that are exacerbated in neurological disabled populations [71].
This lack of participation in physical activities in PD patients has been predicted to correlate to their
increase in energy consumption, leading an increase in symptoms of fatigue and to a subsequent decrease
in physical activity. Through the use of accelerometer output and its association with energy expenditure
in persons with mild-to-moderate Parkinson’s disease, low physical activity levels demonstrated a strong
correlation to energy expenditure [38]. Previous research shows that PD exhibits an increase in walking
abnormalities, causing an increase in metabolic demand and a decrease in physical activity, however
previous research has not shown if the symptom of rigidity could be a key factor that causing this cascade
of secondary symptoms. The purpose of this study was to examine the effects of rigidity on

metabolic cost in Parkinson’s Disease during a walking task, to determine if rigidity and
metabolic cost are correlated.
Research Question and Hypothesis
Question #1: Is there a relationship between parkinsonian rigidity and energy expenditure during
walking?
Hypothesis #1: We predict that increased rigidity will be positively correlated with increased
metabolic cost during walking in PD patients.
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CHAPTER III
The effects of rigidity on energy expenditure during walking and physical activity of daily
living in Parkinson Disease and elderly adults
Alexis K. Nelson, Deranda Lester, Melissa Puppa, Douglas W. Powell
Manuscript in preparation for Neuroscience Letters
INTRODUCTION
Parkinson’s disease (PD) is a movement disorder with motor symptoms of bradykinesia, tremor,
postural instability and rigidity. PD motor symptoms affect the ability of the individual to perform
activities of daily living substantially. Motor symptoms can help to drive non-motor symptoms. Motor
symptoms have secondary effects, one being fatigue. Fatigue is reported as one of the most disabling
nonmotor symptoms of PD [6]. Specifically, 50% of patients report fatigue as one of their most disabling
symptoms [26]. In addition, fatigue could be a driving factor for a decrease in participation shown in
recreational activities for PD, such as social, hobbies or sports, and leads to limited working hours [33].
Overall, fatigue limits the ability of individual to perform daily tasks, which decreases the quality of life.
Activity-induced fatigue is an important subcategory of fatigue which is more clearly identified
by the term “fatigability” [21]. Fatigability is used to set apart activity- or exercise-induced changes that
result in reduced muscle force production as opposed to the perception of fatigue which is manifested as a
general state-of-being associated with an ongoing sense of tiredness or lack of energy. Fatigability is the
result of substrate depletion at the muscle, or the inability to fire motor units (Mus) from the central
structures. An increase in substrate depletion can stem from an increase in demand to the system.
Rigidity increases demand through increases in activation and resistance to move throughout
joint ranges of motion. PD exhibits muscle activation at rest, and increased torque level initially and
throughout motion [13, 67, 89, 91]. All of this states that rigidity leads to greater muscular effort to
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perform similar tasks to healthy controls [36]. Increased muscle activation, potentially could increase the
physiological response of the system to meet the demand.
PD patients exhibit greater metabolic cost of walking compared to healthy controls [16, 39].
Specifically, higher VO2 measurements compared to healthy controls at self-selected paces have been
observed and an increase in oxygen consumption in PD [16, 42, 51]. Net economy of walking is greater in
PD during walking [14, 39, 69]. Increases in metabolic demand has shown to correlate to decreases in
physical activity at home [38]. However, there is a gap in the literature to compare if an increase in
mechanical demand from rigidity correlates to metabolic measurements of walking.
Therefore, the purpose of this study was to find the relationship between rigidity and the
metabolic cost of walking. We hypothesized that rigidity will positively correlate to walking, where
greater rigidity will increase the metabolic cost in PD.

METHODS
Participants
20 participants (10 PD; 10 age-matched controls) between the ages of 50 to 75 years of
age were recruited for this study. Inclusion criteria for individuals with PD will included: (1)
being treated by dopaminergic medication, (2) having the presence of clinical rigidity (> 1, slight
to mild to moderate or marked) in one or both limbs (legs) and (3) having a minimal tremor (< 1,
slight and infrequently present). In addition, participants in the PD group had scores from the
Motor Section (Part III) of the MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
as well as the Hoehn and Yahr scale less than 2.5 provided by their physician [22]. The Hoehn
and Yahr score of 2.5 or less indicates that the patients are all within mild-moderate stages of
PD. The Motor Section (Part III) of the UPDRS includes subjective assessments of rigidity,
bradykinesia, postural instability and gait impairment. Part III motor score of greater than 15 to
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indicate moderate showings of motor symptoms. All potential participants with PD were prescreened by their movement disorders specialist on the patient’s optimal-ON medication state.
The UPDRS was designed by the Movement Disorder Society and is composed of four sections:
intellectual function, activities of daily living, motor exam and motor complications [1].
Individuals with PD are given a score from a scale of 0 to 4 with 0 being normal or no problems
and 4 being severe problems for each question on the exam. During the motor assessment,
physicians are taught to move the patients’ limb passively through a range of motion and rate the
evoked resistance using the previously mentioned scale with 4 meaning the “range of motion [is]
achieved with difficulty”. Based on UPDRS scores and physician feedback, individuals with PD
were classified by disease severity. Additional exclusion criteria included any comorbidities such
as any cardiovascular diseases, dementia, etc. from being able to perform the protocol in addition
to any lower extremity injuries within the previous 6 months.
Control subjects were age – matched to participants with PD and will have no history of
neurological disorders. Healthy controls performed the motor section (Part III) of the MDSUnified Parkinson’s Disease Rating Scale to indicate that all participants were “healthy” and did
not exhibit any motor symptoms. A score of 0 for all of Part III MDS-UPDRS were required
from healthy participants in order to participate. Any participant with an ankle range of motion
smaller than 35 degrees or knee range of motion smaller than 60 degrees or a history of lower
extremity condition that would affect ankle or knee joint ranges of motion were excluded. Any
musculoskeletal injuries or health related disabilities that would affect the participant’s walking
pattern in the lower extremity within the recent 6 months were also excluded for participation.
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Experimental Protocol
Participants visited the Musculoskeletal Analysis Laboratory (MAL) once for
examination and testing. Individuals were screened for inclusion in this study, screening will
include the Mini-Mental State Exam, and provide written informed consent. Following screening
and consent, testing will occur in the following order: (1) complete the Parkinson’s Fatigue
Survey (PFS-16), anthropometric measurements (measurements will include: age, sex, height
and weight) (2) completion of maximal voluntary isometric contractions at the knee (3) rigidity
testing at the knee and repeat steps (2) and (3) for the ankle (4) completion of over ground
walking task of three trials at a preferred and maximal self-selected pace (5) placement of
reflective markers and (6) treadmill walking at a pace equal to their over ground walking selfselected preferred pace for 6 minutes with the use of the metabolic cart, and (7) distribution of
the accelerometer.
Rigidity Testing
Following anthropometric assessments, each participant will perform a maximal
voluntary isometric contraction (MVIC) in an isokinetic dynamometer (HUMAC, CSMi Inc,
Boston, MA) for ankle and knee flexors and extensors. All rigidity testing were performed on the
most affected limb for PD patients and the dominant limb for controls. The MVIC were used to
identify peak force output and rate of force development of the extensors and flexors of the ankle
and knee. Participants were asked to “push as hard as you can” against the dynamometer arm and
strapped into the device to minimize risk of excess movement and injury. Participants remained
in the dynamometer for passive compliance testing at the ankle and knee. This protocol allows
for quantification of rigidity in a similar manner that physicians diagnose patients. During this
portion, the isokinetic dynamometer moved the participant’s passive limb through a range of
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motion while recording the resistance torques applied by the lower extremity soft tissues. Given
that the participant is passive, the resulting torque measured by the dynamometer would be a
result of the resistance applied by passive tissues. Previous literature suggests that this method of
testing adequately quantifies both the neural simultaneously as non-neural contributions to
rigidity because the application to the joints allows for activation without muscle input.
Therefore this ‘activation’ is a representation of passive tissue deformation during a range of
motion [62, 74, 90]. This would be classified as the non-neural part of rigidity and would in turn
be the resulting contribution to the passive torque. At the ankle joint, participants will be moved
through a range of motion equal to 30 degrees (15 degrees of dorsiflexion; 15 degrees of
plantarflexion) and at the knee joint with a range of motion equal to 60 degrees (60 degrees
flexion; 0 degrees extension). The dynamometer will perform the continuous passive motion
(flexion/extension) at each joint for a period of 45 seconds at two velocities: 60 deg/sec and 180
deg/sec.
Over Ground Walking
Following rigidity testing, a total of six over ground walking trials will be performed
across a 3-meter walkway for the preferred walking velocity (three trails) and maximal walking
velocity (three trials). A pair of infrared timing gates (Lafayette Instruments) were used to
determine the walking speed of the participant over the center 3 meters of the walkway. An
average of the three trials will be used as the participant’s self-selected walking pace and
maximal walking pace. The preferred walking pace was maintained during the treadmill walking
trials. Following over ground walking trials, participants rested as needed prior to continuation
of the experimental protocol.
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Experimental Equipment
Following overground walking, retro-reflective markers were placed bilaterally on the
participant’s upper and lower extremity including; pelvis, thigh, shank and feet to measure
individual segment motion during treadmill walking trials using a 9-camera motion capture
system (150 Hz, Qualisys AB, Goteburg, Sweden). For static markers, retroreflective markers
were placed on the first and fifth metatarsal heads, the medial and lateral placement of the
malleolus for the ankle and epicondyles of the knee, and the iliac crest of the pelvis and greater
trochanter of the hip.
Treadmill Walking
Once the markers were placed, participants walked for six minutes at the participants
preferred velocity on a force imbedded treadmill to record ground reaction forces (GRFs; 1500
Hz, Bertec Inc., Columbus, Ohio USA), three-dimensional kinematics and indirect calorimetry
using a metabolic measurement system (TrueOne, ParvoMedics, Sandy, UT). The ground
reaction forces collected in the walking trial were used to find internal joint moments. Indirect
calorimetry compares the concentrations of gases within the room to the concentrations of gases
expired by the participant to determine the quantity of oxygen consumed by the participant
during a given task. Participants performed a 6-minute treadmill walking task while threedimensional kinematics and energy expenditure is recorded. Gait kinematics were recorded in
60 second intervals stating at the beginning of each minute during the 6-minute treadmill
walking task while energy expenditure was collected continuously throughout the treadmill
walking protocol.
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Data Analysis
Key outcome variables of the study included parkinsonian rigidity, metabolic cost of
walking, and physical activity. Parkinsonian rigidity was quantified by the rigidity work score,
angular impulse and slope of the extension and flexion angle. Angular impulse was calculated as
the torque value integrated with respect to time (Nm · sec). Angular impulse used the negative
slope angle determined by the start and stop of the extension or flexion of the joint movement
(ankle or knee), which is calculated as the passive resistance torque integrated with respect to
joint angle. Rigidity work score is calculated by the integral of torque with respect to joint angle
(Nm · deg).
Metabolic cost of walking was quantified as the average volume of oxygen consumed
during the third to sixth minutes of treadmill walking task. Metabolic cost data from the first two
minutes were discarded as the data represent acute metabolic responses to activity and are not
reflective of a stable metabolic cost of the treadmill walking task.
Statistical Analysis
To investigate relationships between independent variables (metabolic cost of walking
and rigidity) and determine significant differences in walking velocity, energy expenditure and
rigidity score one-tailed independent sample t tests were performed with significance level set at
alpha = 0.05. Cohen’s d effect sizes will be computed to determine the magnitude of differences
in dependent variables. For Cohen’s D of effect sizes: small d < 0.6, moderate: 0.6 < d < 1.2, and
large: d > 1.2 [35]. A correlation analysis was used to quantify the relationship of energy
expenditure and rigidity scores. R – squared will be quantified if a meaningful moderate or above
correlation were found to find an explanation for the variance.
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RESULTS
[Table 1 here]
Table 1 shows participant information summaries. Our findings observed that within our
sample, height and weight were significant with a large effect size (p = 0.01, d = 1.15, and p =
0.01, d = 1.26, respectively) where both height and weight were greater in the PD group
compared to the healthy controls. In addition, the UPDRS part three motor examination were
also significant with a large effect size (p < 0.01, d = 6.11) where PD had a greater score than the
control condition.
[Table 2 here]
Table 2 summarizes all velocity measurements; overground and treadmill. Our findings
observed no difference between groups for the participant’s preferred or maximum walking
during the overground session (p = 0.22, d = 0.37, and p = 0.40, d = 0.12). However, treadmill
preferred walking velocity showed significant differences with a moderate effect size between
the groups where the controls preferred to walk faster than the PD group (p = 0.05, d = 0.8).
Further, both the PD and control group observed significant differences between their
overground and treadmill walking velocities where the treadmill speed was slower than the
preferred overground velocities (PD p < 0.01; Control p = 0.02).
[Table 3 here]
Table 3 summarizes all metabolic measurements. For energy consumption, no significant
differences were found between VO2 measured in ml/kg/min or VO2 in L/min, or VO2
normalized to treadmill velocity in meters per second (mps). However, a moderate effect size
was observed for the efficiency of the task of VO2 · mps -1 (d = 0.62). Effect sizes were not
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notable for VO2 measured as mL · kg -1 min -1 (d = 0.45), or VO2 measured as L · min -1 (d =
0.23).
[Table 4 here]

Ankle rigidity measures are stated in Table 4. Rigidity measurements included rigidity
work score, slope, impulse, peak dorsiflexion and plantarflexion in degrees. At the ankle all
variables observed statistically significances, except for extension impulse, and peak degree
measurements, extension and flexion (p = 0.126, d = 0.55, p = 0.269, d = 0.29, and p = 0.168, d =
0.44, respectively). Total rigidity work score, and components to calculate total rigidity work
score (extension and flexion) observed statistically significances with a large effect size (p=
0.014, d = 1.1, p= 0.034, d = 0.91, and p= 0.007, d = 1.29, respectively). Flexion impulse
observed statistically significance with a moderate effect size (p = 0.050, d= 0.80). Extension
and flexion slope observed statistically significances with a large effect size (p = 0.019, d = 1.02
and p = 0.007, d = 1.26).
[Table 5 here]
In table 5, knee rigidity measurements are observed. At the knee, all measurements were
statistically significant and had a large effect size. For rigidity work score, total, flexion and
extension work scores were statistically significant with a large effect size (p < 0.01, d = 1.84, p
< 0.01, d = 1.48, and p < 0.01, d = 1.67, respectively). Extension and flexion impulse were
statistically significant with a large effect size (p < 0.01, d = 1.48 and p < 0.01, d = 1.67).
Extension and flexion slope were statistically significant with a large effect size (p = 0.026, d =
0.99 and p < 0.01, d = 1.80).
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[Table 6 here]
Table 6 reports the correlation analysis between metabolic and rigidity measurements at
the ankle. Positive moderate correlations were observed between rigidity work score
measurements (total, flexion and extension), and flexion impulse for all metabolic measurements
in the PD group and a p value was run for the total rigidity work score from the Pearson product
correlation coefficient for all metabolic measures (total: VO2 L · min -1: r = 0.69 and p = 0.044,
0.60, 0.76, and 0.69; VO2 · mps -1 r = 0.67 and p = 0.048, 0.60, 0.72, and 0.67; VO2 mL · kg -1 ·
min -1: r = 0.49 and p = 0.188, 0.42, 0.56, and 0.49; VO2 · mps -1 · kg -1: r = 0.49 and p = 0.197,
0.43, 0.54, and 0.48, respectively). Positive weak correlations were observed between ankle
slope measurements, extension and flexion, compared to all metabolic measurements in the PD
group (Extension: VO2 L · min -1: r = 0.23, 0.28; VO2 · mps -1 r = 0.28, 0.30, VO2 mL · kg -1 ·
min -1: r = -0.03, 0.08; VO2 · mps -1 · kg -1: r = 0.07, 0.12, respectively). For controls, all
correlations were weak except for flexion work observed a moderate correlation in VO2 L · min 1

and VO2 mL · kg -1 · min -1 (r = 0.31, 0.32, respectively). Only statistically significant rigidity

measurements were included in the correlation to metabolic measures. A p value was determined
for total rigidity work measurements for all VO2 measurements from the Pearson product
correlation analysis (AVO2 L · min -1 p = 0.245, absolute AVO2 · mps -1 p = 0.386, VO2 mL · kg1

· min -1 p = 0.740, VO2 · mps -1 p = 0.865).
[Table 7 here]
In table 7 reports all observed correlations at the knee for rigidity and metabolic

measures. At the PD knee group, A positive moderate correlations were observed between total
rigidity work score and two metabolic measures of VO2 L · min -1 and efficiency of VO2 (L · min
-1

· mps -1) in the PD group (r = 0.43, p = 0.433 and r = 0.33, p = 0.386 respectively). A positive
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moderate correlation was observed for extension rigidity work score two metabolic measures of
VO2 L · min -1 and efficiency of VO2 (L · min -1 · mps -1) in the PD group (r = 0.45 and r = 0.32,
respectively). For the controls, a positive moderate correlation was observed between extension
rigidity work score and impulse for VO2 mL · kg -1 · min -1 (r = 0.31 and r = 0.31, respectively).
A positive moderate correlation was observed between flexion work score and VO2 L · min -1 in
the PD group (r =0.31), and the controls observed a negative moderate correlation between
flexion work and efficiency of VO2 in two measures L · min -1 · mps -1 and VO2 · mps -1 · kg -1 (r
= -0.36, -0.32, respectively). For extension impulse, a moderate correlation was observed for
VO2 L · min -1 and VO2 L · min -1 · mps -1 (r = 0.45 and r = 0.32, respectively) and for controls, a
moderate positive correlation was observed for VO2 mL · kg -1 · min -1 (r = 0.31). For flexion
impulse a positive moderate correlation was found for VO2 L · min -1 (r = 0.31) in the PD group
and for the controls for VO2 L · min -1 · mps -1 and VO2 · mps -1 · kg -1 found a negative moderate
correlation (r = -0.36 and -0.32, respectively). For extension slope, between all metabolic
measures found a negative moderate correlation, (VO2 L · min -1: r = -0.44, VO2 · mps -1 r = 0.43, VO2 mL · kg -1 · min -1: r =-0.36, VO2 · mps -1 · kg -1: r =-0.36, respectively). All
correlations observed weak positive or negative relationships in the controls between extension
slop and all metabolic measurements (VO2 L · min -1: r = 0.17, VO2 · mps -1 r = 0.15, VO2 mL ·
kg -1 · min -1: r = -0.11, VO2 · mps -1 · kg -1: r =-0.04, respectively). Flexion slope in the PD
group observed negative moderate correlations for VO2 L · min -1 and VO2 · mps -1 (r = -0.47,
and r = -0.44, respectively) and a positive moderate correlation for the control group between
VO2 · mps -1 (r= 0.51). All other measures between PD and controls for flexion slope and
metabolic measures were weak correlations. A p value was determined for total rigidity work
measurements for all VO2 measurements from the Pearson product correlation analysis (AVO2 L
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· min -1 p = 0.044, absolute AVO2 · mps -1 p = 0.048, VO2 mL · kg-1 · min -1 p = 0.188, VO2 ·
mps -1 p = 0.197).
Discussion
Purpose and Major Findings
The purpose of this study was to examine the effects of rigidity on metabolic cost in
Parkinson’s Disease during a walking task, to determine if rigidity and metabolic cost are
correlated. The major findings of the current study demonstrate that Parkinson’s patients on
optimal-ON medications do not exhibit significant differences in metabolic cost compared to
healthy controls, however, there is a moderate positive correlation between metabolic cost and
rigidity where an increase in rigidity will subsequently increase the metabolic cost of walking.
Rigidity
PD patients showed greater rigidity compared to healthy controls. Previous research
shows rigidity work score, slope and impulse were greater in PD compared to healthy controls
during similar methods in protocol for the wrist instead of the ankle or knee [67]. In optimalON medication states, previous findings show that PD has steeper slope values for extension and
flexion for rigidity at the wrist, similar to our findings at the ankle and knee [91]. This
potentially is due to the counter effect of the stretch reflex overcoming rigidity force with
optimal-ON medication states to lower overall rigidity work score. Rigidity work score closely
correlates to clinical assessments of rigidity, however elastic forces are not included when
measuring work values [18, 20]. Angular impulse and rigidity slope measurements are
component of the rigidity work score. Angular impulse has been stated to reflect the relationship
between total resistive torque and time, by inclusion of all components of the resistive torque.
This indicates that elastic and non-elastic components are a part of rigidity [29]. However
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previous literature examined angular impulse during medication “off period” for at least 12 hours
prior to data collection. Levodopa medications have been shown to offset the severity of rigidity
score in previous literature [91]. This should indicate differences in our results where our
patients were on optimal-ON medication diminishing some rigidity symptoms, however at ankle
and knee impulse measurements were still statistically different compared to the healthy
controls.
Metabolic Measurements
PD group had similar energy expenditure rates compared to healthy controls. Comparing
our results to previous literature, our results show different outcomes for metabolic
measurements due to our studies inclusion of “optimal-ON” medication timing for data
collections. Our VO2 results compared to previous research are similar in controls to comfortable
pace, however PD patients varied compared between the two studies where our average VO2 was
9.30±3.93 and theirs 11.5±2.8 for their slower and comfortable pace VO2 13.1±2.8 [38]. This
difference could be due to the task demand between the groups were not the same
physiologically. This difference could be potentially due to the difficulty of walking for PD
patients mechanically inhibiting the ability for patients to walk at the pace that is needed to reach
a physiological increase in demand compared to controls, which is also shown through the
difference in treadmill speed between the groups.
Further, compared to a separate study where VO2 measured as ml · kg -1 min -1 during an
ergometer max test showed similar results where PD did not show significant differences from
healthy controls. This lack of difference shown could be due to the demand of the disease was
not significant enough in an ergometer task to show metabolic differences and exonerated PD
disease walking symptoms from the task to overall lower the demand from patients; similar to
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lowering treadmill velocity, decreasing the demand of the task in the PD group compared to
controls [14, 69]. The lack of controls for physical activity levels, medication state of the PD
group and a difference in protocol due to velocity deficits all help to explain differences in
findings to previous literature.
Metabolic Relation to Rigidity
It was hypothesized that an increase in rigidity would positively correlate to an increase
in energy expenditure. While no statistical significance was observed between groups for
metabolic measurements alone, our findings support our hypothesis where an increase in rigidity
positively correlated to an increase in energy expenditure for PD. By normalizing for weight and
velocity we observe a positive moderate correlation between rigidity and metabolic measures at
the ankle (Figure 1) and knee (Figure 2). Therefore, we postulate that due to the difference in
velocity between the PD and Healthy controls, this is a measure of the efficiency of the system to
perform the walking task. In PD there is less efficiency to perform a similar task to the healthy
controls when normalizing for velocity on the treadmill.
[Figure 1 here]
[Figure 2 here]
Greater rigidity work scores positively correlate to VO2 in PD patients. Comparing to
previous literature our findings are similar. There is a gap in the literature examining rigidity
correlations to metabolic measurements in PD patients, however in healthy older adults, greater
stiffness values in lower extremity joints have correlated to an increase in metabolic work in
older adults [55]. As rigidity is a passive stiffening of the tissues instead of an active stiffness
value, rigidity increases stiffness around the joint and therefore the larger rigidity work score at
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the knee and ankle could potentially contribute to the higher energy expenditure in Parkinson’s
patients.
Comments and Limitations
There are several limitations to this study. The sample that was recruited was not gendermatched evenly for PD and controlled groups. This could affect metabolic data for men and
women have different reported averages for several metabolic measures [50]. In addition, our
statistical power could be inefficient to see statistical differences for metabolic measurements
due to our small sample size.
Conclusions and Future Research
Overall, rigidity affects metabolic cost of walking where greater rigidity increases the
metabolic cost. During daily activities PD patients utilize more energy compared to healthy
controls to complete everyday tasks such as walking. This potentially could increase the amount
of fatigue PD patients experience daily and have reported in previous literature to be one of the
most disabling symptoms of the disease [26]. However, analyzing rigidity to energy expenditure
during walking only explains part of fatigue. Future research should compare walking mechanics
on a treadmill in PD compared to healthy controls. The metabolic demand between PD and
healthy controls were not different, however potentially the mechanical demand differed between
the two groups to equate to similar VO2 findings where mechanical demand is defined by
differences seen in treadmill velocity. In addition, this study was performed on optimal-ON
medication states, future research should expand to off-medication states or non-optimal on to
notice the effects of PD during non-optimal settings to better correlate to experiences of patients
who experience dyskinesia. Further, inclusion of physical activity levels to correlate to in-
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laboratory experiences could benefit the progress of how rigidity effects metabolic measures of
walking outside of laboratory settings.
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APPENDICES
Appendix A: Tables
Table 1. Participant Information (mean ± SD).

Group

PD

CON

p value, Cohen’s D

Height

177.6±9.7

165.2±11.7

0.01*, 1.15

Weight

97.9±19.8

74.1±17.3

0.01*, 1.26

Age

64.8±7.9

66.1±4.5

0.33, 0.2

Sex

8 M: 2F

4 M: 6 F

---

MMSE

29.3±0.8

29.7±0.5

0.13, 0.54

PFS-16

0.90±1.66

0.67±1.66

0.38, 0.14

UPDRS- Motor

31.3±7.2

0.0±0.0

< 0.01*, 6.11

Table 1 Demographics Summary. Height measured in centimeters (cm). Weight measured in
kilograms (kg). UPDRS- Motor only includes the part three motor examination.

37

Table 2. Walking Velocity (mean ± SD).
Group

PD

CON

p value, Cohen’s D

Preferred

1.14±0.18

1.20±0.11

0.22, 0.37

Maximum

1.63±0.33

1.60±0.32

0.40, 0.12

Treadmill

0.93±0.24

1.10±0.16

0.05*, 0.8

Table 2 Walking Velocity Summary. All velocity stated above is measured in meters per second
(m/s). The data is the average of all the PD patients and the control groups.

Table 3. Metabolic Summary (mean ± SD).
38

Metabolic Measurement

PD

CON

p value, Cohen’s D

VO2 L · min -1

0.92±0.43

0.83±0.36

0.31, 0.23

VO2 · mps -1

1.05±0.58

0.76±0.34

0.10, 0.62

VO2 ml · kg -1 min -1

9.30±3.93

10.89±3.05

0.17, 0.45

VO2 · mps -1

10.7±5.6

9.1±4.1

0.17, 0.45

Table 3 Metabolic Summary. VO2 is measured in two ways: in L · min -1 and ml · kg -1 min -1.
Metabolic efficiency is measured as VO2 in L · min -1 or ml · kg -1 min -1 over meters per second
(mps).
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Table 4. Ankle Rigidity (mean ± SD).
PD

CON

p value, Cohen’s D

Extension

97.9±33.5

73.7±17.5

0.034*, 0.91

Flexion

71.0±21.6

48.8±11.1

0.007*, 1.29

Total

169.91±53.02

122.46±24.2

0.014*, 1.13

Extension

1.68±0.58

1.38±0.49

0.126, 0.55

Flexion

1.27±0.42

0.95±0.40

0.050*, 0.80

Extension

0.202±0.132

0.017±0.221

0.019*, 1.02

Flexion

0.286±0.149

0.116±0.118

0.007*, 1.26

DF

-11.504±4.039

-12.489±2.542

0.269, 0.29

PF

19.503±0.040

19.169±1.066

0.168, 0.44

Rigidity Measurement
Rigidity Work Score
Nm · deg

Impulse Nm· s

Slope
Nm · deg -1 · s -1

Peak Deg

Table 4 Ankle Rigidity Summary. Extension and Flexion values for Slope measured in Nm · deg
-1 -1
s , Impulse in Nm · s, and Rigidity work score in Nm · deg in flexion, extension and total for
mean, standard deviations, and statistical measures. Deg = degrees, DF = dorsiflexion, PF =
plantarflexion.
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Table 5. Knee Rigidity (mean ± SD).
PD

CON

p value, Cohen’s D

Extension

102.88±25.34

72.00±14.84

< 0.01*, 1.49

Flexion

129.83±39.86

75.82±22.43

<0.01*, 1.67

Total

232.71±54.48

147.82±35.57

<0.01*, 1.84

Extension

1.72±0.42

1.20±0.25

< 0.01*, 1.49

Flexion

2.17±0.67

1.27±0.37

< 0.01*, 1.67

Extension

-0.38±0.14

-0.27±0.06

0.026*, 0.99

Flexion

-0.45±0.12

-0.26±0.09

<0.01*, 1.80

Rigidity Measurement
Rigidity Work Score
Nm · deg

Impulse Nm ·s

Slope
Nm · deg -1 s -1

Table 5 Knee Rigidity Summary. Extension and Flexion values for Slope measured in Nm · deg 1 -1
s , Impulse in Nm · s, and Rigidity work score in Nm · deg in flexion, extension and total for
mean, standard deviations, and statistical measures.
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Table 6. Correlation Ankle Analysis (r values).

Metabolic Measure
Group
AVO2 L · min -1
AVO2 · mps
VO2 mL · kg-1 · min -1
VO2 · kg -1 · min -1

PD
CON
PD
CON
PD
CON
PD
CON

Rigidity
Work Score

Ext Work

Flex
Work

Flex
Impulse

Ext
Slope

Flex
Slope

0.69
0.35
0.67
0.15
0.49
0.23
0.49
-0.03

0.60
0.15
0.60
0.21
0.42
0.13
0.43
-0.04

0.76
0.31
0.72
0.00
0.56
0.32
0.54
0.00

0.69
0.27
0.67
-0.03
0.49
0.22
0.48
-0.01

0.23
0.20
0.28
0.10
-0.03
-0.03
0.07
-0.04

0.28
-0.08
0.30
0.02
0.08
-0.10
0.12
-0.11

Table 6. Correlation Analysis showing the relationship between Metabolic and Rigidity
Measurements at the ankle. Only statistically significant rigidity measurements were included in
the correlation to metabolic measures. A p value was determined for total rigidity work
measurements for all VO2 measurements from the Pearson product correlation analysis (AVO2 L
· min -1 p = 0.245, absolute AVO2 · mps -1 p = 0.386, VO2 mL · kg-1 · min -1 p = 0.740, VO2 ·
mps -1 p = 0.865).
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Table 7. Knee Correlation Analysis (r values).

Metabolic Measure

Group

AVO2 L · min -1

PD
CON
PD
CON
PD
CON
PD
CON

AVO2 · mps -1
VO2 mL · kg-1 · min -1
VO2 · mps -1

Rigidity
Work
Score
0.43
-0.23
0.33
-0.18
0.13
0.06
0.07
-0.18

Ext
Work

Flex
Work

Ext
Impulse

Flex
Impulse

Ext
Slope

Flex
Slope

0.45
-0.11
0.32
0.11
0.29
0.31
0.20
0.06

0.31
-0.21
0.25
-0.36
-0.01
-0.11
-0.03
-0.32

0.45
-0.11
0.32
0.11
0.29
0.31
0.20
0.06

0.31
-0.12
0.25
-0.36
-0.01
-0.11
-0.03
-0.32

-0.44
0.17
-0.43
0.15
-0.36
-0.11
-0.36
-0.04

-0.47
0.28
-0.44
0.51
-0.24
0.15
-0.21
0.20

Table 7. Correlation Analysis showing the relationship between Metabolic and Rigidity
Measurements at the knee. Only statistically significant rigidity measurements were included in
the correlation to metabolic measures. A p value was determined for total rigidity work
measurements for all VO2 measurements from the Pearson product correlation analysis (AVO2 L
· min -1 p = 0.044, absolute AVO2 · mps -1 p = 0.048, VO2 mL · kg-1 · min -1 p = 0.188, VO2 ·
mps -1 p = 0.197).
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Appendix B: Figures
Figure 1. Knee Correlation Analysis
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Figure 1 Summary. Knee VO2 measured in L / min / mps correlated to total rigidity work score
measured in Nm · deg.
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Figure 2. Ankle Total Rigidity by VO2 L · min -1
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Figure 2 Summary. Ankle VO2 measured in L / min / mps correlated to total rigidity work score
measured in Nm · deg.
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